-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Elected as an Executive Director Unit of the Hebei Provincial Digital Economy Federation
Category:
发布时间：2025-12-19
【概要描述】
On December 18, the Second Members’ (Representatives’) Conference of the Hebei Provincial Digital Economy Association was held at the Hebei Hall. During the conference, Shijiazhuang Sihua Pharmaceutical Group was elected as an executive director unit of the association. This recognition not only underscores the group’s dedicated efforts in digital transformation over recent years, but also highlights its leading role in fostering the integrated innovation of the pharmaceutical industry and digital technologies.
On December 18, the Second Members’ (Representatives’) Conference of the Hebei Provincial Digital Economy Association was held at the Hebei Hall. During the conference, Shijiazhuang Sihua Pharmaceutical Group was elected as an executive director unit of the association. This recognition not only underscores the group’s deep commitment to digital transformation in recent years but also highlights its leading role in driving the integrated innovation of the pharmaceutical industry and digital technologies.
The Hebei Provincial Digital Economy Association was established in 2020 under the supervision of the Provincial Department of Industry and Information Technology. As a leading industry association that brings together key players in the province’s digital economy, it is committed to advancing the industrialization of digital technologies and the digital transformation of traditional industries, fostering deep integration between the real economy and the digital economy, and building a collaborative platform for coordinated development among government, enterprises, academia, and research institutions. The Group’s election as an executive director unit this time signifies a further enhancement of its influence within Hebei’s digital economy development landscape.
In recent years, in response to the emerging trend of high-quality development in the pharmaceutical industry, Shijiazhuang Sihua Pharmaceutical Group has adhered to a dual-engine growth strategy driven by “innovation-driven development and digital empowerment,” actively launched the “Artificial Intelligence Plus” initiative, and systematically advanced digital transformation across all processes and multiple application scenarios. Focusing on core business functions such as financial management, manufacturing, quality control, and supply-chain collaboration, the Group has continuously increased its investment in intelligent technologies, establishing a smart manufacturing system centered on ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and APS (Advanced Planning and Scheduling) systems. This has enabled greater flexibility, transparency, and precise control over production processes, significantly enhancing operational efficiency and market responsiveness.
Meanwhile, the Group has been building data-driven capabilities to seamlessly integrate and intelligently analyze data across finance, R&D, production, marketing, human resources, and other functional areas. By leveraging data to optimize decision-making and drive business innovation, the Group is fostering closer collaboration between R&D and production and accelerating the rapid translation of research outcomes into commercial value. During the 14th Five-Year Plan period, thanks to a series of digital transformation achievements, the Group was successively recognized as a “National Pilot for the Integrated Development of Advanced Manufacturing and Modern Services,” an “Outstanding Smart Manufacturing Scenario,” an “Innovative Leading Application Case in the Industrial Internet,” and a benchmark case for industrial internet in Hebei Province, thereby establishing a digital transformation roadmap that serves as a model for the industry.
“Being elected as an executive director unit has provided us with greater opportunities to stay abreast of cutting-edge developments in the information technology industry and to learn from and exchange insights with experts and peers,” said the head of the Group’s Information Management Center. Moving forward, the Group will leverage the Federation’s platform to actively strengthen communication and collaboration with industry experts and institutions, further deepen the application of digital technologies across the entire pharmaceutical value chain, and focus on building integrated digital competitiveness spanning research, production, sales, and services. This effort will drive the enterprise toward continuous advancement in intelligence, green practices, and integration, while contributing more expertise and resources to accelerating the high-quality development of Hebei Province’s digital economy and the transformation, upgrading, quality improvement, and efficiency enhancement of its biopharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091